Kate L. J. Ellacott

Kate L. J. Ellacott

Auto-generated profile, based on publicly available information

Kate L. J. Ellacott

Department of Clinical and Biomedical Sciences University of Exeter Medical School Exeter UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2004 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
WFWei Fan
Wei Fan
KEKate L J Ellacott
Kate L J Ellacott
IHIlia G Halatchev
Ilia G Halatchev
KTKanji Takahashi
Kanji Takahashi
PYPinxuan Yu
Pinxuan Yu
RCRoger D Cone
Roger D Cone

8 March 2010 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
Arion KennedyArion Kennedy
Arion Kennedy
KEKate L. J. Ellacott
Kate L. J. Ellacott
VKVictoria L. King
Victoria L. King
AHAlyssa H Hasty
Alyssa H Hasty
The metabolic syndrome (MetS) is characterized by obesity concomitant with other metabolic abnormalities such as hypertriglyceridemia, reduced high-density lipoprotein levels, elevated blood pressure and raised fasting glucose levels. The precise definition of MetS, the relationships of its metabolic features, and what initiates it, are debated. However, obesity is on the rise worldwide, and its association with these metabolic symptoms increases the risk for diabetes and cardiovascular disease (among many other diseases). Research needs to determine the mechanisms by which obesity and MetS increase the risk of disease. In light of this growing epidemic, it is imperative to develop animal models of MetS. These models will help determine the pathophysiological basis for MetS and how MetS increases the risk for other diseases. Among the various animal models available to study MetS, mice are the most commonly used for several reasons. First, there are several spontaneously occurring obese mouse strains that have been used for decades and that are very well characterized. Second, high-fat feeding studies require only months to induce MetS. Third, it is relatively easy to study the effects of single genes by developing transgenic or gene knockouts to determine the influence of a gene on MetS. For these reasons, this review will focus on the benefits and caveats of the most common mouse models of MetS. It is our hope that the reader will be able to use this review as a guide for the selection of mouse models for their own studies.

1 July 2010 in Cell Metabolism
Verified
Journal Article
Closed access
KEKate L.J. Ellacott
Kate L.J. Ellacott
GMGregory J. Morton
Gregory J. Morton
SWStephen C. Woods
Stephen C. Woods
PTPatrick Tso
Patrick Tso
MSMichael W. Schwartz
Michael W. Schwartz

1 January 2004 in Recent Progress in Hormone Research
Verified
Journal Article
Closed access
KEK. L.J. Ellacott
K. L.J. Ellacott
The importance of the central melanocortin system in the regulation of energy balance is highlighted by studies in transgenic animals and humans with defects in this system. Mice that are engineered to be deficient for the melanocortin-4 receptor (MC4R) or pro-opiomelanocortin (POMC) and those that overexpress agouti or agouti-related protein (AgRP) all have a characteristic obese phenotype typified by hyperphagia, increased linear growth, and metabolic defects. Similar attributes are seen in humans with haploinsufficiency of the MC4R. The central melanocortin system modulates energy homeostasis through the actions of the agonist, alpha-melanocyte-stimulating hormone (alpha-MSH), a POMC cleavage product, and the endogenous antagonist AgRP on the MC3R and MC4R. POMC is expressed at only two locations in the brain: the arcuate nucleus of the hypothalamus (ARC) and the nucleus of the tractus solitarius (NTS) of the brainstem. This chapter will discuss these two populations of POMC neurons and their contribution to energy homeostasis. We will examine the involvement of the central melanocortin system in the incorporation of information from the adipostatic hormone leptin and acute hunger and satiety factors such as peptide YY (PYY(3-36)) and ghrelin via a neuronal network involving POMC/cocaine and amphetamine-related transcript (CART) and neuropeptide Y (NPY)/AgRP neurons. We will discuss evidence for the existence of a similar network of neurons in the NTS and propose a model by which this information from the ARC and NTS centers may be integrated directly or via adipostatic centers such as the paraventricular nucleus of the hypothalamus (PVH).

1 January 2014 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
LBLaura B. Buckman
Laura B. Buckman
AHAlyssa H Hasty
Alyssa H Hasty
DFDavid K. Flaherty
David K. Flaherty
CBChristopher T. Buckman
Christopher T. Buckman
MTMisty M. Thompson
Misty M. Thompson
KEKate L.J. Ellacott
Kate L.J. Ellacott

1 June 2004 in Endocrinology
Verified
Journal Article
Open access
PDF file
IHIlia G. Halatchev
Ilia G. Halatchev
KEKate L. J. Ellacott
Kate L. J. Ellacott
WFWei Fan
Wei Fan
RCRoger D. Cone
Roger D. Cone
Peptide YY3–36 (PYY3–36), a peptide released postprandially by the gut, has been demonstrated to inhibit food intake. Little is known about the mechanism by which PYY3–36 inhibits food intake, although the peptide has been shown to increase hypothalamic proopiomelanocortin (POMC) mRNA in vivo and to activate POMC neurons in an electrophysiological slice preparation. Understanding the physiology of PYY3–36 is further complicated by the fact that some laboratories have had difficulty demonstrating inhibition of feeding by the peptide in rodents. We demonstrate here that, like cholecystokinin, PYY3–36 dose-dependently inhibits food intake by approximately 20–45% over a 3- to 4-h period post ip administration, with no effect on 12-h food intake. This short-lived satiety effect is not seen in animals that are not thoroughly acclimated to handling and ip injection, thus potentially explaining the difficulty in reproducing the effect. Surprisingly, PYY3–36 was equally efficacious in inducing satiety in wild-type and melanocortin-4 receptor (MC4-R)-deficient mice and thus does not appear to be dependent on MC4-R signaling. The expression of c-Fos, an indirect marker of neuronal activation, was also examined in forebrain and brainstem neurons after ip treatment with a dose of PYY3–36 shown to induce satiety. The peptide induced no significant neuronal activation in the brainstem by this assay, and only modest activation of hypothalamic POMC neurons. Thus, unlike cholecystokinin, PYY3–36-induced satiety is atypical, because it does not produce detectable activation of brainstem satiety centers and is not dependent on MC4-R signaling.